Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

RecruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

October 24, 2018

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions

Atopic Dermatitis (AD)Asthma

Interventions

DRUG

dupilumab

Dupilumab cohort

Trial Locations (1)

RECRUITING

Regeneron Research Site, La Jolla